Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 10/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 9/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 4/20 | 0.33 |
| ▸ | UBA6 | A0AVT1 | 3/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21129817 | 0.84 | PRMT5 (0.33) | PRMT5WDR77NNMTUBA6SLC22A12 | |
| SCHEMBL25049137 | 0.82 | NNMT (0.36) | PRMT5WDR77PIP4K2ANNMT | |
| SCHEMBL22002062 | 0.80 | ALDH1A1 (0.34) | — | |
| SCHEMBL24595470 | 0.80 | PRMT5 (0.35) | PRMT5WDR77NNMTSLC22A12 | |
| SCHEMBL25047772 | 0.78 | PRMT5 (0.31) | PRMT5WDR77PIP4K2A | |
| SCHEMBL25048850 | 0.76 | NNMT (0.36) | NNMTUBA6 | |
| SCHEMBL19344195 | 0.76 | PRMT5 (0.37) | PRMT5WDR77NNMT | |
| SCHEMBL20049423 | 0.76 | PRMT5 (0.37) | PRMT5WDR77NNMT | |
| SCHEMBL16769947 | 0.75 | PRMT5 (0.44) | PRMT5WDR77PIP4K2ANNMTUBA6 | |
| SCHEMBL21089762 | 0.75 | PRMT5 (0.36) | PRMT5WDR77NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371433-A1 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371433-A1 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | PRMT5, PRMT1, PRMT8 | PRMT5 1/4885WDR77 90/4885ACACB 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.